Biotech firm Idenix Pharmaceuticals (NASDAQ:IDIX) announced Monday that it will not continue developing two of its pipeline drugs: hepatitis C therapy IDX184, which was in phase 2B clinical trial, and another HCV nucleotide polymerase inhibitor, IDX19368.
The FDA put IDX184 on hold in August of last year -- and placed IDX 19368 on clinical hold -- after poor results from a phase 2 trial from competitor Brystol-Myers Squibb's BMS-986094, which encountered "cardiac adverse events," according to Idenix's release. Idenix President and CEO Ron Renaud commented on the company's direction following the decision, saying in the release that it would continue to "maintain our strong presence in developing nucleotide polymerase inhibitors for HCV based on our broad discovery platform."
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Biotech M&A: Do We Need a New Driver?
Hepatitis C acquisitions like we've seen from Gilead, Bristol-Myers Squibb, and Merck can't last forever.
3 Stocks That Soared Stupendously This Week
2 of this week's biggest health-care winners scored triple-digit gains with another jumping over 40%. Here's how they did it.
This Week in Biotech: Tulipmania Ensues in the Hepatitis C Sector
Five clinical updates that made waves in the biotech sector this week, as well as the surprising buyout that still has Wall Street abuzz.